{"protocolSection":{"identificationModule":{"nctId":"NCT00241644","nctIdAliases":["NCT00598468"],"orgStudyIdInfo":{"id":"102248"},"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants","officialTitle":"Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants"},"statusModule":{"statusVerifiedDate":"2016-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2005-10"},"primaryCompletionDateStruct":{"date":"2008-06","type":"ACTUAL"},"completionDateStruct":{"date":"2008-06","type":"ACTUAL"},"studyFirstSubmitDate":"2005-10-18","studyFirstSubmitQcDate":"2005-10-18","studyFirstPostDateStruct":{"date":"2005-10-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-06-18","resultsFirstSubmitQcDate":"2009-06-18","resultsFirstPostDateStruct":{"date":"2009-08-04","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-10-27","lastUpdatePostDateStruct":{"date":"2016-12-09","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The primary objective of this study is to determine if the GSK Biologicals' human rotavirus (HRV) vaccine (pooled HRV groups) given concomitantly with routine expanded program on immunisation (EPI) vaccinations can prevent severe rotavirus gastroenteritis (≥11 on the 20-point Vesikari scoring system \\[Ruuska, 1990\\]) caused by the circulating wild-type RV strains during the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 5.\n\nThe primary objective will be reached if the lower limit of the 95% confidence interval (CI) on vaccine efficacy is \\>0%.\n\nThe Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.","detailedDescription":"The study will have three groups: Rotarix 3-Dose Group, Rotarix 2-Dose Group and Placebo Group. Three-dose immunisation will be administered in healthy infants at approximately 6, 10, and 14 weeks of age. Routine EPI vaccinations will be administered concomitantly with the study vaccines. This study will also evaluate immunogenicity and safety relative to the placebo."},"conditionsModule":{"conditions":["Infections, Rotavirus"],"keywords":["Rotavirus gastroenteritis","HRV vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":2089,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rotarix 3-Dose Group","type":"EXPERIMENTAL","description":"Subjects received 3 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.","interventionNames":["Biological: Rotarix™"]},{"label":"Rotarix 2-Dose Group","type":"EXPERIMENTAL","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ vaccine given concomitantly with routine EPI vaccines.","interventionNames":["Biological: Rotarix™","Biological: Placebo"]},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR","description":"Subjects received 3 doses of placebo given concomitantly with routine EPI vaccines.","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Rotarix™","description":"Two or Three doses, oral administration","armGroupLabels":["Rotarix 2-Dose Group","Rotarix 3-Dose Group"],"otherNames":["GSK Biologicals' HRV vaccine"]},{"type":"BIOLOGICAL","name":"Placebo","description":"One or three doses, oral administration.","armGroupLabels":["Placebo Group","Rotarix 2-Dose Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","timeFrame":"From 2 weeks after the last vaccine or placebo dose up to 1 year of age"}],"secondaryOutcomes":[{"measure":"Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain, Classified by Rotavirus Type","description":"Number of subjects presenting with three or more looser than normal stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.\n\nRotavirus types were G1 wild type (WT) and non-G1.","timeFrame":"From 2 weeks after the last vaccine or placebo dose up to 1 year of age"},{"measure":"Number of Subjects Reporting Any Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample.","timeFrame":"From 2 weeks after the last vaccine or placebo dose up to 1 year of age"},{"measure":"Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","timeFrame":"From the first vaccine or placebo dose up to 1 year of age"},{"measure":"In South Africa, Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","timeFrame":"From 2 weeks after the third dose of vaccine or placebo up to 1 year of age"},{"measure":"Number of Subjects Reporting Severe Gastroenteritis of Any Cause","description":"Number of subjects with gastroenteritis (three or more looser than normal stools or watery stools within a day) that scored ≥ 11 on the 20-point Vesikari scoring system.","timeFrame":"From 2 weeks after the last vaccine or placebo dose up to 1 year of age"},{"measure":"Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain","description":"RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.","timeFrame":"From 2 weeks after the last vaccine or placebo dose up to 1 year of age"},{"measure":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","timeFrame":"During the period from 2 weeks after the last dose of vaccine or placebo until study end"},{"measure":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","timeFrame":"During the period from 1 year of age to study end"},{"measure":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Episode Caused by the Circulating Wild-type RV Strains","description":"RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.","timeFrame":"During the period from 2 weeks after the last dose of vaccine or placebo until study end"},{"measure":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Episode Caused by the Circulating Wild-type RV Strains","description":"RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.","timeFrame":"During the period from 1 year of age to study end"},{"measure":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strains, Classified by Rotavirus Type","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.\n\nRotavirus types were G1 wild type (WT) and non-G1.","timeFrame":"During the period from 2 weeks after the last dose of vaccine or placebo until study end"},{"measure":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strains, Classified by Rotavirus Type","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.\n\nRotavirus types were G1 wild type (WT) and non-G1.","timeFrame":"During the period from 1 year of age to study end"},{"measure":"Number of Subjects With Adverse Events (AEs) or Serious Adverse Events (SAEs) Leading to Drop Out","description":"An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.\n\nAn SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.","timeFrame":"From the first dose of vaccine or placebo up to end of the study"},{"measure":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.","timeFrame":"From the first dose of vaccine or placebo up to end of the study"},{"measure":"Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies in Initially Seronegative Subjects","description":"An initially seronegative subject is a subject whose IgA antibody concentration was below the assay cut-off value of 20 Units per milliliter (U/mL) before administration of the first vaccine dose.","timeFrame":"One month after the last vaccine dose"},{"measure":"Number of Seroconverted Subjects","description":"Seroconverted subjects are defined as subjects with appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/mL in subjects initially (i.e. prior to the first dose of vaccine or placebo) seronegative for rotavirus.","timeFrame":"One month after the last vaccine or placebo dose"},{"measure":"Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies","description":"Geometric mean concentrations are given as Units per milliliter (U/mL).","timeFrame":"One month after the last vaccine or placebo dose"},{"measure":"Number of Seropositive Subjects","description":"Seropositive subjects are defined as subjects with anti-rotavirus IgA antibody concentration ≥ 20 U/mL.","timeFrame":"One month after the last vaccine or placebo dose"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.\n* A male or female child between, and including, 5 and 10 weeks of age at the time of the first study vaccination.\n* Written informed consent obtained from the parent or guardian of the subject who is of legal age\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n* In South Africa, birth weight \\> 2000 grams or if weight unknown, gestation period \\> 36 weeks.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product\n* Planned administration of a vaccine not foreseen by the study protocol within 14 days before each dose of study vaccine(s) and ending 14 days after.\n* Chronic administration (defined as more than 14 days) of immunosuppressants since birth.\n* History of use of experimental rotavirus vaccine.\n* Previous routine vaccination except Bacille Calmette-Guérin (BCG), hepatitis B virus (HBV) and oral poliovirus (OPV) vaccination at birth\n* Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract, intussusception or other medical condition determined to be serious by the investigator.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination\n* History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.\n* Acute disease at the time of enrolment.\n* Gastroenteritis within 7 days preceding the first study vaccine administration\n* Previous confirmed occurrence of rotavirus gastroenteritis (RV GE).\n* A family history of congenital or hereditary immunodeficiency.\n* Administration of immunoglobulins and/or blood products since birth or planned administration during the study period.\n* History of any neurologic disorders or seizures.\n* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.","healthyVolunteers":true,"sex":"ALL","minimumAge":"5 Weeks","maximumAge":"10 Weeks","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Bangwe, Blantyre","zip":"3","country":"Malawi"},{"facility":"GSK Investigational Site","city":"Limbe, Blantyre","zip":"3","country":"Malawi"},{"facility":"GSK Investigational Site","city":"Ndirande, Blantyre","zip":"3","country":"Malawi"},{"facility":"GSK Investigational Site","city":"Zingwanga, Blantyre","zip":"3","country":"Malawi","geoPoint":{"lat":-15.78499,"lon":35.00854}},{"facility":"GSK Investigational Site","city":"Brits","zip":"0250","country":"South Africa","geoPoint":{"lat":-25.63473,"lon":27.78022}},{"facility":"GSK Investigational Site","city":"Diepkloof, Soweto","country":"South Africa"},{"facility":"GSK Investigational Site","city":"Diepsloot","country":"South Africa","geoPoint":{"lat":-25.93312,"lon":28.01213}},{"facility":"GSK Investigational Site","city":"Eldorado Park Ext 9, Soweto","country":"South Africa","geoPoint":{"lat":-26.26781,"lon":27.85849}},{"facility":"GSK Investigational Site","city":"Karenpark","zip":"0118","country":"South Africa"},{"facility":"GSK Investigational Site","city":"Mamelodi","country":"South Africa","geoPoint":{"lat":-24.59764,"lon":31.02379}},{"facility":"GSK Investigational Site","city":"Mamelodi East","country":"South Africa","geoPoint":{"lat":-25.67912,"lon":28.35096}},{"facility":"GSK Investigational Site","city":"Shoshanguve","country":"South Africa"},{"facility":"GSK Investigational Site","city":"Tembisa","country":"South Africa","geoPoint":{"lat":-26.00979,"lon":28.22762}}]},"referencesModule":{"references":[{"type":"BACKGROUND","citation":"Cunliffe N et al. Efficacy of human rotavirus vaccine RIX4414 in Africa during the first year of life. Abstract presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Disease (ESPID), Brussels, Belgium, 9-13 June 2009."},{"pmid":"22520135","type":"BACKGROUND","citation":"Cunliffe NA, Witte D, Ngwira BM, Todd S, Bostock NJ, Turner AM, Chimpeni P, Victor JC, Steele AD, Bouckenooghe A, Neuzil KM. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine. 2012 Apr 27;30 Suppl 1(0 1):A36-43. doi: 10.1016/j.vaccine.2011.09.120."},{"type":"BACKGROUND","citation":"Cunliffe NA et al. Efficacy of Human Rotavirus Vaccine RIX4414 in Malawian Infants in the first two years of life. Abstract presented at the 6th African Rotavirus Symposium, Johannesburg, South Africa, 2-3 August 2010."},{"pmid":"20107214","type":"BACKGROUND","citation":"Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, Neuzil KM. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010 Jan 28;362(4):289-98. doi: 10.1056/NEJMoa0904797."},{"type":"BACKGROUND","citation":"Madhi S et al. Efficacy of the human rotavirus vaccine RIX4414 against rotavirus G2P[4]/g8p[4] strains in South African infants. Abstract presented at the 6th world congress of the World Society for Pediatric Infectious Diseases (WSPID), Buenos Aires, Argentina, 18-22 November 2009."},{"pmid":"22520136","type":"BACKGROUND","citation":"Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S, Bouckenooghe A, Neuzil KM, Steele AD. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine. 2012 Apr 27;30 Suppl 1:A44-51. doi: 10.1016/j.vaccine.2011.08.080."},{"pmid":"22520123","type":"BACKGROUND","citation":"Nakagomi T, Nakagomi O, Dove W, Doan YH, Witte D, Ngwira B, Todd S, Duncan Steele A, Neuzil KM, Cunliffe NA. Molecular characterization of rotavirus strains detected during a clinical trial of a human rotavirus vaccine in Blantyre, Malawi. Vaccine. 2012 Apr 27;30 Suppl 1(0 1):A140-51. doi: 10.1016/j.vaccine.2011.09.119."},{"type":"BACKGROUND","citation":"Neuzil K et al. Immunogenicity of human rotavirus vaccine RIX4414 in South African and Malawian infants. Abstract presented at the 6th world congress of the World Society for Pediatric Infectious Diseases (WSPID), Buenos Aires, Argentina, 18-22 November 2009."},{"type":"BACKGROUND","citation":"Neuzil K et al. RIX4414 is protective against severe RVGE caused by diverse rotavirus serotypes during the first year of life in African infants. Abstract presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Disease (ESPID), Brussels, Belgium, 9-13 June 2009."},{"type":"BACKGROUND","citation":"Steele AD et al. Efficacy of human rotavirus vaccine, Rotarix™ against severe gastroenteritis caused by diverse circulating rotavirus strains in African infants. Abstract presented at the 7th World Congress for World Society for Pediatric Infectious Diseases (WSPID). Melbourne, Australia, 16-19 November 2011."},{"type":"BACKGROUND","citation":"Steele D et al. Diverse circulating rotavirus strains during the first year of life in African infants. Abstract presented at 10th International symposium on dsRNA Viruses, Hamilton Island, QLD, Australia, 21-25 June 2009."},{"pmid":"29564996","type":"DERIVED","citation":"Gruber JF, Becker-Dreps S, Hudgens MG, Brookhart MA, Thomas JC, Jonsson Funk M. Timing and predictors of severe rotavirus gastroenteritis among unvaccinated infants in low- and middle-income countries. Epidemiol Infect. 2018 Apr;146(6):698-704. doi: 10.1017/S0950268818000626. Epub 2018 Mar 22."},{"pmid":"27895844","type":"DERIVED","citation":"Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, Neuzil KM. Effect of human rotavirus vaccine on severe diarrhea in African infants. Malawi Med J. 2016 Sep;28(3):108-114."},{"pmid":"22974466","type":"DERIVED","citation":"Steele AD, Neuzil KM, Cunliffe NA, Madhi SA, Bos P, Ngwira B, Witte D, Todd S, Louw C, Kirsten M, Aspinall S, Van Doorn LJ, Bouckenooghe A, Suryakiran PV, Han HH. Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infect Dis. 2012 Sep 13;12:213. doi: 10.1186/1471-2334-12-213."}],"seeAlsoLinks":[{"label":"Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.","url":"https://www.clinicalstudydatarequest.com"}],"availIpds":[{"id":"102248","type":"Individual Participant Data Set","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register. The results of this study 102248 are summarised with study 111274 on the GSK Clinical Study Register."},{"id":"102248","type":"Informed Consent Form","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"102248","type":"Statistical Analysis Plan","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"102248","type":"Dataset Specification","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"102248","type":"Annotated Case Report Form","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"102248","type":"Clinical Study Report","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"102248","type":"Study Protocol","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Of the total of 4941 subjects enrolled in this study, 2 subjects were allocated a subject number but did not get any study vaccine administered. Hence, only 4939 subjects were considered as 'started'.\n\nFor the second follow-up period, as mentioned in the protocol the results are presented for Rotarix Pooled and Placebo Groups only.","recruitmentDetails":"Only subjects from Malawi and from Cohort 2 South Africa were asked to continue the study for a second follow-up period (Year 2).","groups":[{"id":"FG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"FG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"FG002","title":"Placebo Group","description":"Subjects received 3 doses of placebo."},{"id":"FG003","title":"Rotarix Pooled Group","description":"Subjects received 2 or 3 doses of Rotarix™ (rotavirus vaccine)."}],"periods":[{"title":"First Efficacy Period (Year 1)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1647"},{"groupId":"FG001","numSubjects":"1651"},{"groupId":"FG002","numSubjects":"1641"},{"groupId":"FG003","numSubjects":"3298"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1420"},{"groupId":"FG001","numSubjects":"1383"},{"groupId":"FG002","numSubjects":"1392"},{"groupId":"FG003","numSubjects":"2803"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"227"},{"groupId":"FG001","numSubjects":"268"},{"groupId":"FG002","numSubjects":"249"},{"groupId":"FG003","numSubjects":"495"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"45"},{"groupId":"FG002","numSubjects":"45"},{"groupId":"FG003","numSubjects":"91"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"8"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"59"},{"groupId":"FG001","numSubjects":"74"},{"groupId":"FG002","numSubjects":"81"},{"groupId":"FG003","numSubjects":"133"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"116"},{"groupId":"FG001","numSubjects":"142"},{"groupId":"FG002","numSubjects":"116"},{"groupId":"FG003","numSubjects":"258"}]},{"type":"Non-compliance","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Return dates not reliable","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Vaccinated at regular clinic","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Subject's parent passed away","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]}]},{"title":"Second Efficacy Period (Year 2)","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"771"},{"groupId":"FG001","numSubjects":"754"},{"groupId":"FG002","numSubjects":"746"},{"groupId":"FG003","numSubjects":"1525"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"710"},{"groupId":"FG001","numSubjects":"697"},{"groupId":"FG002","numSubjects":"682"},{"groupId":"FG003","numSubjects":"1407"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"61"},{"groupId":"FG001","numSubjects":"57"},{"groupId":"FG002","numSubjects":"64"},{"groupId":"FG003","numSubjects":"118"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"20"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"7"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"43"},{"groupId":"FG002","numSubjects":"46"},{"groupId":"FG003","numSubjects":"86"}]},{"type":"Consenting parent passed away","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"BG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"BG002","title":"Placebo Group","description":"Subjects received 3 doses of placebo."},{"id":"BG003","title":"Rotarix Pooled Group","description":"Subjects received 2 or 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1647"},{"groupId":"BG001","value":"1651"},{"groupId":"BG002","value":"1641"},{"groupId":"BG003","value":"3298"},{"groupId":"BG004","value":"8237"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"weeks","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6.3","spread":"0.92"},{"groupId":"BG001","value":"6.4","spread":"0.98"},{"groupId":"BG002","value":"6.4","spread":"0.97"},{"groupId":"BG003","value":"6.4","spread":"0.95"},{"groupId":"BG004","value":"6.4","spread":"0.95"}]}]}]},{"title":"Gender","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"811"},{"groupId":"BG001","value":"839"},{"groupId":"BG002","value":"800"},{"groupId":"BG003","value":"1650"},{"groupId":"BG004","value":"4100"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"836"},{"groupId":"BG001","value":"812"},{"groupId":"BG002","value":"841"},{"groupId":"BG003","value":"1648"},{"groupId":"BG004","value":"4137"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","populationDescription":"Analysis was performed on the According-to-Protocol (ATP) cohort for efficacy","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From 2 weeks after the last vaccine or placebo dose up to 1 year of age","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1496"},{"groupId":"OG001","value":"1478"},{"groupId":"OG002","value":"2974"},{"groupId":"OG003","value":"1443"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"70"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain, Classified by Rotavirus Type","description":"Number of subjects presenting with three or more looser than normal stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.\n\nRotavirus types were G1 wild type (WT) and non-G1.","populationDescription":"Analysis was performed on the ATP cohort for efficacy","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From 2 weeks after the last vaccine or placebo dose up to 1 year of age","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1496"},{"groupId":"OG001","value":"1478"},{"groupId":"OG002","value":"2974"},{"groupId":"OG003","value":"1443"}]}],"classes":[{"title":"G1 WT","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"23"}]}]},{"title":"Non-G1","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"39"},{"groupId":"OG003","value":"47"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample.","populationDescription":"Analysis was performed on the ATP cohort for efficacy","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From 2 weeks after the last vaccine or placebo dose up to 1 year of age","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1496"},{"groupId":"OG001","value":"1478"},{"groupId":"OG002","value":"2974"},{"groupId":"OG003","value":"1443"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"167"},{"groupId":"OG003","value":"174"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From the first vaccine or placebo dose up to 1 year of age","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1647"},{"groupId":"OG001","value":"1651"},{"groupId":"OG002","value":"3298"},{"groupId":"OG003","value":"1641"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"68"},{"groupId":"OG003","value":"83"}]}]}]},{"type":"SECONDARY","title":"In South Africa, Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strain","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","populationDescription":"Analysis was performed on the ATP cohort for efficacy, only for the subset of subjects in South Africa who were fully vaccinated before the beginning of the rotavirus season.\n\nFor this analysis, data from Rotarix 2-dose Group and Rotarix 3-dose Group were pooled into one group (Rotarix pooled Group).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From 2 weeks after the third dose of vaccine or placebo up to 1 year of age","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"478"},{"groupId":"OG001","value":"468"},{"groupId":"OG002","value":"946"},{"groupId":"OG003","value":"468"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"20"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Severe Gastroenteritis of Any Cause","description":"Number of subjects with gastroenteritis (three or more looser than normal stools or watery stools within a day) that scored ≥ 11 on the 20-point Vesikari scoring system.","populationDescription":"Analysis was performed on the ATP cohort for efficacy.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From 2 weeks after the last vaccine or placebo dose up to 1 year of age","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1496"},{"groupId":"OG001","value":"1478"},{"groupId":"OG002","value":"2974"},{"groupId":"OG003","value":"1443"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"122"},{"groupId":"OG002","value":"256"},{"groupId":"OG003","value":"178"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strain","description":"RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.","populationDescription":"Analysis was performed on the ATP cohort for efficacy","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From 2 weeks after the last vaccine or placebo dose up to 1 year of age","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1496"},{"groupId":"OG001","value":"1478"},{"groupId":"OG002","value":"2974"},{"groupId":"OG003","value":"1443"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"142"},{"groupId":"OG003","value":"156"}]}]}]},{"type":"SECONDARY","title":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","populationDescription":"The analysis was performed on the According-To-Protocol (ATP) cohort for efficacy of the combined efficacy follow-up periods.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"During the period from 2 weeks after the last dose of vaccine or placebo until study end","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1873"},{"groupId":"OG003","value":"891"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"81"},{"groupId":"OG003","value":"66"}]}]}]},{"type":"SECONDARY","title":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis (RV GE) Caused by the Circulating Wild-type Rotavirus Strains","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.","populationDescription":"The analysis was performed on the According-To-Protocol (ATP) cohort for efficacy of the second efficacy period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"During the period from 1 year of age to study end","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1500"},{"groupId":"OG003","value":"712"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"21"}]}]}]},{"type":"SECONDARY","title":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Episode Caused by the Circulating Wild-type RV Strains","description":"RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.","populationDescription":"The analysis was performed on the ATP cohort for efficacy of the combined efficacy follow-up periods.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"During the period from 2 weeks after the last dose of vaccine or placebo until study end","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1873"},{"groupId":"OG003","value":"891"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"118"}]}]}]},{"type":"SECONDARY","title":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects Hospitalized and/or With Supervised Re-hydration Therapy Due to Rotavirus Gastroenteritis (RV GE) Episode Caused by the Circulating Wild-type RV Strains","description":"RV GE caused by the circulating wild-type rotavirus strain: three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample collected as soon as possible after the symptoms begin.","populationDescription":"The analysis was performed on the ATP cohort for efficacy of the second efficacy period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"During the period from 1 year of age to study end","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1500"},{"groupId":"OG003","value":"712"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"26"}]}]}]},{"type":"SECONDARY","title":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strains, Classified by Rotavirus Type","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.\n\nRotavirus types were G1 wild type (WT) and non-G1.","populationDescription":"The analysis was performed on the ATP cohort for efficacy of the combined efficacy follow-up periods.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"During the period from 2 weeks after the last dose of vaccine or placebo until study end","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1873"},{"groupId":"OG003","value":"891"}]}],"classes":[{"title":"G1 WT","categories":[{"measurements":[{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"20"}]}]},{"title":"Non-G1","categories":[{"measurements":[{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"48"}]}]}]},{"type":"SECONDARY","title":"For Subjects in Cohort 2 South Africa and the Cohort in Malawi: Number of Subjects With Severe Rotavirus Gastroenteritis Caused by the Circulating Wild-type Rotavirus Strains, Classified by Rotavirus Type","description":"Number of subjects presenting with three or more looser than normal stools or watery stools within a day, occurring after administration of dose 1 of study vaccine in which rotavirus other than vaccine strain was identified in a stool sample with a score ≥ 11 on the 20-point Vesikari scoring system.\n\nRotavirus types were G1 wild type (WT) and non-G1.","populationDescription":"The analysis was performed on the ATP cohort for efficacy of the second efficacy period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"During the period from 1 year of age to study end","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1500"},{"groupId":"OG003","value":"712"}]}],"classes":[{"title":"G1 WT","categories":[{"measurements":[{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"11"}]}]},{"title":"Non-G1","categories":[{"measurements":[{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"10"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Adverse Events (AEs) or Serious Adverse Events (SAEs) Leading to Drop Out","description":"An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.\n\nAn SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From the first dose of vaccine or placebo up to end of the study","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1647"},{"groupId":"OG001","value":"1651"},{"groupId":"OG002","value":"3298"},{"groupId":"OG003","value":"1641"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"111"},{"groupId":"OG003","value":"56"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From the first dose of vaccine or placebo up to end of the study","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1647"},{"groupId":"OG001","value":"1651"},{"groupId":"OG002","value":"3298"},{"groupId":"OG003","value":"1641"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"199"},{"groupId":"OG002","value":"421"},{"groupId":"OG003","value":"246"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies in Initially Seronegative Subjects","description":"An initially seronegative subject is a subject whose IgA antibody concentration was below the assay cut-off value of 20 Units per milliliter (U/mL) before administration of the first vaccine dose.","populationDescription":"Analysis was performed on the ATP cohort for immunogenicity, only for initially seronegative subjects.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Units per milliliter (U/mL)","timeFrame":"One month after the last vaccine dose","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"115"},{"groupId":"OG002","value":"221"},{"groupId":"OG003","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.6","lowerLimit":"38.9","upperLimit":"82.3"},{"groupId":"OG001","value":"79.4","lowerLimit":"54.7","upperLimit":"115.2"},{"groupId":"OG002","value":"67.5","lowerLimit":"51.9","upperLimit":"87.8"},{"groupId":"OG003","value":"23.4","lowerLimit":"16.8","upperLimit":"32.5"}]}]}]},{"type":"SECONDARY","title":"Number of Seroconverted Subjects","description":"Seroconverted subjects are defined as subjects with appearance of anti-rotavirus IgA antibody concentration ≥ 20 U/mL in subjects initially (i.e. prior to the first dose of vaccine or placebo) seronegative for rotavirus.","populationDescription":"Analysis was performed on the ATP cohort for immunogenicity, only for inititally seronegative subjects.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"One month after the last vaccine or placebo dose","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"115"},{"groupId":"OG002","value":"221"},{"groupId":"OG003","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"72"},{"groupId":"OG002","value":"129"},{"groupId":"OG003","value":"25"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration of Anti-rotavirus Immunoglobulin A (IgA) Antibodies","description":"Geometric mean concentrations are given as Units per milliliter (U/mL).","populationDescription":"Analysis was performed on the ATP cohort for immunogenicity.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"U/mL","timeFrame":"One month after the last vaccine or placebo dose","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1160"},{"groupId":"OG001","value":"1138"},{"groupId":"OG002","value":"2298"},{"groupId":"OG003","value":"1125"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.5","lowerLimit":"65.2","upperLimit":"80.6"},{"groupId":"OG001","value":"67.9","lowerLimit":"60.8","upperLimit":"75.9"},{"groupId":"OG002","value":"70.2","lowerLimit":"65.0","upperLimit":"75.8"},{"groupId":"OG003","value":"21.8","lowerLimit":"19.8","upperLimit":"24.0"}]}]}]},{"type":"SECONDARY","title":"Number of Seropositive Subjects","description":"Seropositive subjects are defined as subjects with anti-rotavirus IgA antibody concentration ≥ 20 U/mL.","populationDescription":"Analysis was performed on the ATP cohort for immunogenicity.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"One month after the last vaccine or placebo dose","groups":[{"id":"OG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine)."},{"id":"OG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group."},{"id":"OG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1160"},{"groupId":"OG001","value":"1138"},{"groupId":"OG002","value":"2298"},{"groupId":"OG003","value":"1125"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"756"},{"groupId":"OG001","value":"706"},{"groupId":"OG002","value":"1462"},{"groupId":"OG003","value":"262"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Rotarix 2-dose Group","description":"Subjects received 1 dose of placebo followed by 2 doses of Rotarix™ (rotavirus vaccine).","seriousNumAffected":222,"seriousNumAtRisk":1647,"otherNumAffected":0,"otherNumAtRisk":1647},{"id":"EG001","title":"Rotarix 3-dose Group","description":"Subjects received 3 doses of Rotarix™ (rotavirus vaccine).","seriousNumAffected":199,"seriousNumAtRisk":1651,"otherNumAffected":0,"otherNumAtRisk":1651},{"id":"EG002","title":"Rotarix Pooled Group","description":"For some data analyses, the 2 Groups receiving Rotarix (Rotarix 2-dose Group \\& Rotarix 3-dose Group) were pooled into Rotarix pooled Group.","seriousNumAffected":421,"seriousNumAtRisk":3298,"otherNumAffected":0,"otherNumAtRisk":3298},{"id":"EG003","title":"Placebo Group","description":"Subjects received 3 doses of placebo.","seriousNumAffected":246,"seriousNumAtRisk":1641,"otherNumAffected":0,"otherNumAtRisk":1641}],"seriousEvents":[{"term":"Gastroenteritis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":94,"numAtRisk":1647},{"groupId":"EG001","numAffected":67,"numAtRisk":1651},{"groupId":"EG002","numAffected":161,"numAtRisk":3298},{"groupId":"EG003","numAffected":104,"numAtRisk":1641}]},{"term":"Pneumonia","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":55,"numAtRisk":1647},{"groupId":"EG001","numAffected":54,"numAtRisk":1651},{"groupId":"EG002","numAffected":109,"numAtRisk":3298},{"groupId":"EG003","numAffected":64,"numAtRisk":1641}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":1647},{"groupId":"EG001","numAffected":25,"numAtRisk":1651},{"groupId":"EG002","numAffected":54,"numAtRisk":3298},{"groupId":"EG003","numAffected":25,"numAtRisk":1641}]},{"term":"Sepsis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":1647},{"groupId":"EG001","numAffected":28,"numAtRisk":1651},{"groupId":"EG002","numAffected":61,"numAtRisk":3298},{"groupId":"EG003","numAffected":29,"numAtRisk":1641}]},{"term":"Bronchiolitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":1647},{"groupId":"EG001","numAffected":17,"numAtRisk":1651},{"groupId":"EG002","numAffected":38,"numAtRisk":3298},{"groupId":"EG003","numAffected":17,"numAtRisk":1641}]},{"term":"Malaria","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":1647},{"groupId":"EG001","numAffected":25,"numAtRisk":1651},{"groupId":"EG002","numAffected":44,"numAtRisk":3298},{"groupId":"EG003","numAffected":33,"numAtRisk":1641}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":1647},{"groupId":"EG001","numAffected":7,"numAtRisk":1651},{"groupId":"EG002","numAffected":14,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Meningitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":1647},{"groupId":"EG001","numAffected":4,"numAtRisk":1651},{"groupId":"EG002","numAffected":11,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Pneumocystis jiroveci pneumonia","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":1647},{"groupId":"EG001","numAffected":4,"numAtRisk":1651},{"groupId":"EG002","numAffected":8,"numAtRisk":3298},{"groupId":"EG003","numAffected":5,"numAtRisk":1641}]},{"term":"Febrile convulsion","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":1647},{"groupId":"EG001","numAffected":7,"numAtRisk":1651},{"groupId":"EG002","numAffected":11,"numAtRisk":3298},{"groupId":"EG003","numAffected":6,"numAtRisk":1641}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1647},{"groupId":"EG001","numAffected":6,"numAtRisk":1651},{"groupId":"EG002","numAffected":8,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1647},{"groupId":"EG001","numAffected":3,"numAtRisk":1651},{"groupId":"EG002","numAffected":6,"numAtRisk":3298},{"groupId":"EG003","numAffected":4,"numAtRisk":1641}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1647},{"groupId":"EG001","numAffected":3,"numAtRisk":1651},{"groupId":"EG002","numAffected":6,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Kwashiorkor","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1647},{"groupId":"EG001","numAffected":4,"numAtRisk":1651},{"groupId":"EG002","numAffected":7,"numAtRisk":3298},{"groupId":"EG003","numAffected":8,"numAtRisk":1641}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":1647},{"groupId":"EG001","numAffected":2,"numAtRisk":1651},{"groupId":"EG002","numAffected":6,"numAtRisk":3298},{"groupId":"EG003","numAffected":3,"numAtRisk":1641}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":5,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Death","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1647},{"groupId":"EG001","numAffected":2,"numAtRisk":1651},{"groupId":"EG002","numAffected":4,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":2,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":3,"numAtRisk":1641}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":3,"numAtRisk":3298},{"groupId":"EG003","numAffected":3,"numAtRisk":1641}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1647},{"groupId":"EG001","numAffected":2,"numAtRisk":1651},{"groupId":"EG002","numAffected":5,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Bronchitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Pneumonia viral","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":3,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Pyrexia","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":3,"numAtRisk":1651},{"groupId":"EG002","numAffected":4,"numAtRisk":3298},{"groupId":"EG003","numAffected":4,"numAtRisk":1641}]},{"term":"Sudden infant death syndrome","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":2,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Croup infectious","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Marasmus","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1647},{"groupId":"EG001","numAffected":5,"numAtRisk":1651},{"groupId":"EG002","numAffected":8,"numAtRisk":3298},{"groupId":"EG003","numAffected":4,"numAtRisk":1641}]},{"term":"Otitis media","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":3,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Arthritis bacterial","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Encephalitis","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Heart disease congenital","organSystem":"Congenital, familial and genetic disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Ileus paralytic","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Meningitis pneumococcal","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":2,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Otitis media acute","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":3,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Status epilepticus","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":2,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Acquired immunodeficiency syndrome","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Convulsion","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":2,"numAtRisk":1651},{"groupId":"EG002","numAffected":3,"numAtRisk":3298},{"groupId":"EG003","numAffected":3,"numAtRisk":1641}]},{"term":"Fontanelle bulging","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Metabolic acidosis","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":3,"numAtRisk":1641}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":3,"numAtRisk":1641}]},{"term":"Staphylococcal skin infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1647},{"groupId":"EG001","numAffected":4,"numAtRisk":1651},{"groupId":"EG002","numAffected":6,"numAtRisk":3298},{"groupId":"EG003","numAffected":4,"numAtRisk":1641}]},{"term":"Abscess","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Abscess neck","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Adenoidectomy","organSystem":"Surgical and medical procedures","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Asphyxia","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":2,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Blindness","organSystem":"Eye disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Brachial plexus injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Cerebral malaria","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Cyst","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Eczema infected","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Febrile infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Fractured skull depressed","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Herpes simplex","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Hypernatraemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Hyponatraemic syndrome","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Hypovolaemic shock","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Intussusception","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Klebsiella bacteremia","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Meningitis bacterial","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Neuroblastoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Nosocomial infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Parotid abscess","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Pharyngotonsillitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":2,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Postoperative wound infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Respiratory arrest","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Respiratory tract infection viral","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Sepsis neonatal","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Septic shock","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Tuberculosis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":2,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Varicella","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Viral tonsillitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Cachexia","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Cellulitis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":2,"numAtRisk":1641}]},{"term":"Disseminated tuberculosis","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Empyema","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Escherichia urinary tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Grunting","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Haemorrhagic disorder","organSystem":"Blood and lymphatic system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Hypoglycaemic seizure","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Immunosuppression","organSystem":"Immune system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Irritability","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Meningitis tuberculous","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Patent ductus arteriosus","organSystem":"Congenital, familial and genetic disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Perianal abscess","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Pneumonitis chemical","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Soft tissue injury","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Sudden death","organSystem":"General disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Therapeutic agent toxicity","organSystem":"Injury, poisoning and procedural complications","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Urticaria","organSystem":"Skin and subcutaneous tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":3,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Adenoidal hypertrophy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Chemical poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Food poisoning","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Genital rash","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Keratitis herpetic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Phimosis","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Respiratory syncytial virus bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Salmonella sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":1,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Umbilical hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":1,"numAtRisk":3298},{"groupId":"EG003","numAffected":0,"numAtRisk":1641}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Abscess limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Drug toxicity","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Foreign body aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]},{"term":"Strabismus","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":1647},{"groupId":"EG001","numAffected":0,"numAtRisk":1651},{"groupId":"EG002","numAffected":0,"numAtRisk":3298},{"groupId":"EG003","numAffected":1,"numAtRisk":1641}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","phone":"866-435-7343"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D012400","term":"Rotavirus Infections"}],"ancestors":[{"id":"D012088","term":"Reoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"C492457","term":"RIX4414 vaccine"}]}},"hasResults":true}